Axsome Therapeutics (AXSM) Operating Leases: 2023-2025
Historic Operating Leases for Axsome Therapeutics (AXSM) over the last 3 years, with Sep 2025 value amounting to $23.0 million.
- Axsome Therapeutics' Operating Leases rose 257.78% to $23.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.0 million, marking a year-over-year increase of 257.78%. This contributed to the annual value of $6.0 million for FY2024, which is 14.06% down from last year.
- According to the latest figures from Q3 2025, Axsome Therapeutics' Operating Leases is $23.0 million, which was down 2.47% from $23.6 million recorded in Q2 2025.
- Axsome Therapeutics' Operating Leases' 5-year high stood at $23.9 million during Q1 2025, with a 5-year trough of $6.0 million in Q4 2024.
- Over the past 3 years, Axsome Therapeutics' median Operating Leases value was $7.4 million (recorded in 2023), while the average stood at $11.9 million.
- Per our database at Business Quant, Axsome Therapeutics' Operating Leases fell by 16.27% in 2024 and then soared by 257.78% in 2025.
- Over the past 3 years, Axsome Therapeutics' Operating Leases (Quarterly) stood at $7.0 million in 2023, then fell by 14.06% to $6.0 million in 2024, then spiked by 257.78% to $23.0 million in 2025.
- Its Operating Leases was $23.0 million in Q3 2025, compared to $23.6 million in Q2 2025 and $23.9 million in Q1 2025.